Inflammation and Brain Diseases
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (15 October 2023) | Viewed by 4284
Special Issue Editors
Interests: brain diseases; electrophysiology; epilepsy; cortical plasticity
Interests: amyloid proteins; medicinal chemistry; degenerative diseases; drug design; X-ray crystallography; chemical synthesis
Special Issues, Collections and Topics in MDPI journals
Interests: medicinal chemistry; drug discovery; metalloenzyme inhibitors; neurodegenerative diseases; anticancer drugs; CNS agents; chemical synthesis; structure–activity relationship; natural products
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Inflammation is the common denominator of several CNS pathologies. It is now well-accepted that inflammatory pathways are involved in the pathogenesis of several neurodegenerative disorders, such as multiple sclerosis (MS), Parkinson’s disease (PD), and Alzheimer’s disease (AD), and they are known to be activated following neurologic infection, ischemic stroke, and traumatic brain injury. In addition, clinical observations and experimental findings support a link between inflammation and epilepsy. In the brain, the major players in the inflammatory response are resident cellular elements. Microglia and astrocytes are strongly activated in most neurodegenerative diseases and produce a variety of inflammatory mediators. Whether the neuroinflammatory reaction is beneficial or detrimental to disease progression is still a matter of debate. However, in recent decades, most findings have suggested that inflammation exacerbates the pathological manifestation of CNS diseases. This evidence has framed inflammation as a common target for a broad range of CNS diseases. Thus, anti-inflammatory agents could potentially be effective for different pathologies. Approved anti-inflammatory drugs, as well as innovative, multifunctional, and/or hybrid molecules, are fundamental tools both in elucidating pathological pathways of brain diseases and in mitigating disease progression.
This Special Issue aims to provide an overview of approved drugs exploited in brain diseases and to highlight state-of-the-art new compounds under study.
Dr. Chiara Cerri
Dr. Lidia Ciccone
Dr. Susanna Nencetti
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neuroinflammation
- anti-inflammatory drugs
- neurodegenerative disorders
- epilepsy
- drug design
- computational methods
- systemic inflammation
